That can sometimes happen right around Christmas, so we don't know if that will persistCDC: Plenty of H1N1 vaccine everywhere Jan 07, 2010
I just want to remind women and doctors and nurse midwives that antiviral medicine can be a very important treatment for pregnant women who have respiratory illnessCDC: 28 pregnant women dead from H1N1 Oct 01, 2009
We know there are also capsules of the anti-viral medicineCDC: Millions in U.S. had H1N1 last spring Oct 29, 2009
The key now is focusing on the priority groups, children and young adults up through age 24, pregnant women, parents or caretakers of babies under 6 months. People with chronic conditions and health workersDouble H1N1 vaccine, but still not enough Nov 06, 2009
We know that a number of the deaths that we're seeing are occurring outside the hospital where testing is not possibleCDC estimates 22M had H1N1, 3,900 died Nov 12, 2009
Rear Admiral Anne Schuchat, M.D., is the current Interim Deputy Director for Science and Public Health Program at the Centers for Disease Control and Prevention (CDC).
Anne Schuchat graduated with highest honors from Swarthmore College and with honors from Dartmouth Medical School. She served as resident and chief resident in internal medicine at New York University′s Manhattan VA Hospital before beginning her public health career at CDC as an Epidemic Intelligence Service (EIS) officer in NCID.
As Interim Deputy Director for Science and Public Health Program, Dr. Schuchat is focused on ensuring strong science and programmatic approaches are effectively integrated into planning across the agency. She has emphasized prevention of infectious diseases in children. Her emphasis on perinatal group B streptococcal disease prevention has led to an 80 percent reduction in newborn infections and a 75 percent narrowing of racial disparities among sufferers of this infectious disease. She has been instrumental in pre- and post-licensure evaluations of conjugate vaccines for bacterial meningitis and pneumonia and in accelerating availability of these new vaccines in resource-poor countries through WHO and the Global Alliance for Vaccines and Immunization.